Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 studyMarina Chiara Garassino, Inmaculada Ramos García, Byoung Chul Cho et al.|The Lancet Oncology|2018Cited by 579
Phase II prospective study with sorafenib in advanced soft tissue sarcomas after anthracycline-based therapyArmando Santoro, Alexia Bertuzzi, Alessandro Comandone et al.|Annals of Oncology|2012Cited by 54
Italian Cohort of the Nivolumab EAP in Squamous NSCLC: Efficacy and Safety in Patients With CNS MetastasesDiego Cortinovis, Angelo Delmonte, Rita Chiari et al.|Anticancer Research|2019Cited by 38
Validation of the AJCC prognostic stage for HER2-positive breast cancer in the ShortHER trialMaria Vittoria Dieci, PierFranco Conte, Giancarlo Bisagni et al.|BMC Medicine|2019Cited by 25
Efficacy and safety data from patients with advanced squamous NSCLC and brain metastases participating in the nivolumab Expanded Access Programme (EAP) in ItalyPaolo Bidoli, Angelo Delmonte, Rita Chiari et al.|Annals of Oncology|2016Cited by 19